skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Carcinoma of the pancreas: results of irradiation for unresectable lesions

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5005642

From 1973 to 1977, 20 patients who had histologically proven unresectable adenocarcinoma of the pancreas with no distant metastases were irradiated at the Medical College of Wisconsin Affiliated Hospitals. The patients received megavoltage external irradiation to minimum tumor doses ranging between 3000 rad in 4 weeks and 5700 rad in 7 weeks (median 4600 rad in 6 weeks); their actuarial survival was 54% at 12 months and 21% at 24 months. Fourteen patients who received 4500 rad or more in 6 to 7 weeks had a median survival of 13 months. Six patients received less than 4500 rad in 3 to 6 weeks, and their median survival was 7 months. At this writing, three patients are alive and apparently disease free more than 2 years after treatment. Complications were seen in two patients. One died from GI bleeding 2 months after completion of radiation therapy, and the other patient developed pancreatic insufficiency. These results and recent reports in the literature show that aggressive irradiation can result in long-term disease free survival in a small proportion of patients with unresectable pancreatic adenocarcinoma. Further exploitation of this approach alone or combined with chemotherapy is warranted.

Research Organization:
Medical Coll. of Wisconsin Affiliated Hospitals, Milwaukee
OSTI ID:
5005642
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 6:2; Conference: 20. annual meeting of the American Society of Therapeutic Radiologists, Los Angeles, CA, USA, 2 Nov 1978
Country of Publication:
United States
Language:
English

Similar Records

Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation
Journal Article · Wed Nov 01 00:00:00 EST 1989 · International Journal of Radiation Oncology, Biology and Physics; (USA) · OSTI ID:5005642

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study
Journal Article · Wed Mar 15 00:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5005642

Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial
Journal Article · Sun Aug 01 00:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5005642